

PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Arzerra

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	Prescriber Name: Supervising Physician:		
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address: Address:			
City, State ZIP:	City, State ZIP:		
Primary Phone:	Specialty/facility name (if applicable):	
Drug Name and Strength:			
Directions / SIG:			
Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.			
Q1. Is the prescribing physician an Oncologist or Hematolo	ogist?		
Q2. What diagnosis is this drug being prescribed for?			
☐ Chronic lymphocytic leukemia (CLL)			
☐ Other			
Q3. Please provide ICD code(s) for diagnosis			
Q4. Please indicate location of administration.			
☐ Home			
☐ Long Term Care (LTC) facility			
☐ Physician office (drug from office stock- buy and bill)			
☐ Physician office (drug from pharmacy with a prescription	on)		
Q5. Has the patient previously tried and failed Fludara (fludara)	darabine)?		
☐ Yes ☐ No	,		
Q6. Has the patient previously tried and failed Campath (a	lemtuzumab)?		



PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Arzerra

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:			Prescriber Name: Supervising Physician:
Yes	☐ No		<u> </u>
Q7. If the patient If due to bulky aden	` '), is the pa	atient not expected to respond to Campath (alemtuzumab)
☐ Yes	☐ No		
Q8. If the patient I this patient?	nas previously been untreated	for CLL, is	s fludarabine-based therapy is considered inappropriate for
☐ Yes	☐ No		
Q9. If the patient I	nas previously been untreated	for CLL, w	vill Arzerra be used in combination with chlorambucil?
☐ Yes	☐ No		
Q10. Additional C	omments		
	Prescriber Signature		Date
	, ,		ve, I certify that applying the standard review timeframe may enrollee's ability to regain maximum function
			essity denial. Requesting providers may speak to the SWHP medical nity to help impact the decision on a request before coverage has beer
This talecopy transmission of	contains confidential information belonging t	o the sender t	hat is legally privileged. This information is intended only for the use of the individual or

entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are



PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Arzerra

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

	Prescriber Name:
Patient Name:	Supervising Physician:

hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document